Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2013; 19(35): 5910-5916
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5910
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5910
Table 1 Patients’ characteristics (n = 39) n (%)
| Characteristics | No. of patients |
| Age, yr (range) | Median 60 (range, 34-72) |
| Sex | |
| Female | 1 (2.6) |
| Male | 38 (97.4) |
| ECOG performance status | |
| 0 | 4 (10.3) |
| 1 | 32 (82.0) |
| 2 | 3 (7.7) |
| Tumor involved site | |
| Lymph node | 25 (64.1) |
| Lung | 14 (35.9) |
| Liver | 16 (41.0) |
| Bone | 7 (17.9) |
| Number of involved site | |
| 1 | 28 (71.8) |
| 2 | 13 (33.3) |
| ≥ 3 | 4 (10.3) |
| Differentiation | |
| Poor-differentiated | 10 (25.6) |
| Moderate-well differentiated | 23 (59.0) |
| Unknown | 6 (15.4) |
| Prior treatment (cases) | |
| Treatment-naive | 30 (76.9) |
| Radiation | 4 (10.3) |
| Operation | 5 (12.8) |
- Citation: He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang FS, Chen J, Zhu L, Yao YW, Wang W. A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol 2013; 19(35): 5910-5916
- URL: https://www.wjgnet.com/1007-9327/full/v19/i35/5910.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i35.5910